Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia. It also offers MIN-117, a compound that has completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disorder (MDD); and seltorexant, which is in Phase IIb clinical trial for treating insomnia and MDD. The company' preclinical stage product is MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the MIN-117 compound and roluperidone worlwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NERV
CUSIPN/A
Phone617-600-7373
Debt
Debt-to-Equity RatioN/A
Current Ratio15.85
Quick Ratio15.85
Price-To-Earnings
Trailing P/E Ratio-8.19
Forward P/E Ratio-5.92
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.40 per share
Price / Book2.54
Profitability
EPS (Most Recent Fiscal Year)($1.08)
Net Income$-31,520,000.00
Net MarginsN/A
Return on Equity-35.48%
Return on Assets-25.14%
Miscellaneous
Employees12
Outstanding Shares38,750,000
Minerva Neurosciences (NASDAQ:NERV) Frequently Asked Questions
What is Minerva Neurosciences' stock symbol?
Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."
How were Minerva Neurosciences' earnings last quarter?
Minerva Neurosciences Inc (NASDAQ:NERV) announced its quarterly earnings results on Thursday, May, 3rd. The biopharmaceutical company reported ($0.32) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.28) by $0.04. View Minerva Neurosciences' Earnings History.
What price target have analysts set for NERV?
1 Wall Street analysts have issued 12 month price objectives for Minerva Neurosciences' shares. Their forecasts range from $11.00 to $11.00. On average, they expect Minerva Neurosciences' stock price to reach $11.00 in the next twelve months. View Analyst Ratings for Minerva Neurosciences.
Who are some of Minerva Neurosciences' key competitors?
Some companies that are related to Minerva Neurosciences include IMMURON Ltd/S (IMRN), Impax Laboratories (IPXL), Uniqure (QURE), Theravance Biopharma (TBPH), Amneal Pharmaceuticals (AMRX), Apellis Pharmaceuticals (APLS), Athenex (ATNX), Zai Lab (ZLAB), Arrowhead Pharmaceuticals (ARWR), Alder Biopharmaceuticals (ALDR), Revance Therapeutics (RVNC), Eagle Pharmaceuticals (EGRX), Retrophin (RTRX), TG Therapeutics Inc common stock (TGTX) and Esperion Therapeutics (ESPR).
Who are Minerva Neurosciences' key executives?
Minerva Neurosciences' management team includes the folowing people:
- Dr. Rémy Luthringer, Exec. Chairman & CEO (Age 57)
- Mr. Geoffrey Robin Race, Exec. VP, CFO, Chief Bus. Officer & Company Sec. (Age 57)
- Dr. Michael Davidson, Chief Medical Officer (Age 68)
- Mr. Richard Russell, Pres (Age 54)
- Mr. Joseph Reilly, Sr. VP & COO (Age 43)
Has Minerva Neurosciences been receiving favorable news coverage?
Media stories about NERV stock have trended somewhat positive on Monday, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Minerva Neurosciences earned a news impact score of 0.17 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 46.29 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Minerva Neurosciences' major shareholders?
Minerva Neurosciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Highland Capital Management LP (5.80%), BlackRock Inc. (5.06%), Millennium Management LLC (2.31%), JPMorgan Chase & Co. (1.55%), Northern Trust Corp (0.78%) and Artal Group S.A. (0.77%). Company insiders that own Minerva Neurosciences stock include Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Marc D Beer, Mark S Levine, Remy Luthringer and Venture Associates L Index III. View Institutional Ownership Trends for Minerva Neurosciences.
Which institutional investors are selling Minerva Neurosciences stock?
NERV stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., BlackRock Inc. and Northern Trust Corp. Company insiders that have sold Minerva Neurosciences company stock in the last year include Frederick W Ahlholm, Geoff Race, Joseph H Reilly and Remy Luthringer. View Insider Buying and Selling for Minerva Neurosciences.
Which institutional investors are buying Minerva Neurosciences stock?
How do I buy shares of Minerva Neurosciences?
Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Minerva Neurosciences' stock price today?
One share of NERV stock can currently be purchased for approximately $8.65.
How big of a company is Minerva Neurosciences?
Minerva Neurosciences has a market capitalization of $342.93 million. The biopharmaceutical company earns $-31,520,000.00 in net income (profit) each year or ($1.08) on an earnings per share basis. Minerva Neurosciences employs 12 workers across the globe.
How can I contact Minerva Neurosciences?
Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-600-7373 or via email at [email protected]
MarketBeat Community Rating for Minerva Neurosciences (NERV)
MarketBeat's community ratings are surveys of what our community members think about Minerva Neurosciences and other stocks. Vote "Outperform" if you believe NERV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NERV will underperform the S&P 500 over the long term. You may vote once every thirty days.
